Visit https://www.peervoice.com/QKR860 to view the entire programme with slides. After completing “Fatos Pinar Topsever, MD / Jennifer Green, MD - CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Disease in Patients With Type 2 Diabetes”, participants will be able to: Use recommended screening tests to identify chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM); Evaluate current efficacy and safety evidence guiding the use of novel...

Visit https://www.peervoice.com/BSG860 to view the entire programme with slides. After completing “George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action”, participants will be able to: Summarise the evidence supporting the need for the current 2024 COVID-19 vaccination campaign for older adults and vulnerable individuals; and Outline the key recommendations by the World Health Organization (WHO)...

Visit https://www.peervoice.com/HPE860 to view the entire programme with slides. After completing “Carel le Roux, MD, PhD - Prioritising Obesity Care in Our Clinical Practices: Why We Must and How We Can”, participants will be able to: Apply best practices for the screening and formal diagnosis of obesity as a chronic disease; Identify patients who would benefit from treatment or referral for management of obesity; and Evaluate current and emerging strategies for treating obesity as a chronic...

Visit https://www.peervoice.com/TBP860 to view the entire programme with slides. After completing “Meena B. Bansal, MD, FAASLD - The Many Faces of MASH: Recognising Risk, Improving Identification, and Maximising Management in the Primary Care Setting”, participants will be able to: Discuss the pathogenesis and metabolic drivers of metabolic dysfunction-associated steatohepatitis (MASH); Apply risk stratification scores for liver fibrosis; and Develop guideline-recommended management plans for...

Visit https://www.peervoice.com/SCT860 to view the entire programme with slides. After completing “Andreea Ciudin, MD, PhD - Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on the Modernisation of Obesity Care”, participants will be able to: Explain the rationale for screening for and formally diagnosing obesity as a chronic disease; Apply best practices for communication with people who have obesity about the associated risks and treatment options; and Apply a...

Visit https://www.peervoice.com/TUF860 to view the entire programme with slides. After completing “Walter Chow, BScPhm, MD - Better Outcomes for Your Patients Living With Obesity: Practical Management Strategies for Primary Care”, participants will be able to: Review the currently approved obesity pharmacotherapy; Outline practical considerations with obesity pharmacotherapy, such as dosing, titration, and management of safety concerns; and Propose key strategies to individualize obesity...

Visit https://www.peervoice.com/MPR860 to view the entire programme with slides. After completing “Lise Lotte Gluud, MD - Following the Evidence-Based Road: Improving Care for MASH Through Use of Clinical Care Pathways in Primary Care”, participants will be able to: Apply strategies to identify patients who warrant additional screening for metabolic dysfunction-associated steatohepatitis (MASH) based on clinical suspicion and imaging; Discuss serum biomarkers and non-invasive screening...

Visit https://www.peervoice.com/SUE860 to view the entire programme with slides. After completing “Tina Vilsbøll, MD, DMSc - Overcoming Barriers to Basal Insulin in T2DM: Appreciating the Preferences and Perspectives of Patients With T2DM ”, participants will be able to: Explain the rationale for timely initiation of basal insulin treatment in patients with type 2 diabetes mellitus (T2DM); Assess common patient- and provider-level barriers to the use of basal insulin therapy; and Evaluate the...

Visit https://www.peervoice.com/EDT860 to view the entire programme with slides. After completing “Paolo Sbraccia, MD, PhD - Providing State of the Art Care for People With Obesity: Can We Break Free From the Status Quo?”, participants will be able to: Apply guidelines and recommendations for accurate and timely diagnosis of obesity; Manage obesity as a specific, treatable, adiposity-based chronic disease; and Propose management plans for obesity in collaboration with patients through a...

Visit https://www.peervoice.com/SXQ860 to view the entire programme with slides. After completing “Harpreet Bajaj, MD, MPH - Innovating Our Approach to the Initiation of Insulin in T2DM: The Why and the How”, participants will be able to: Evaluate the current guideline-recommended place of basal insulin therapy in the management of type 2 diabetes mellitus (T2DM); Identify common contributors to delayed initiation of basal insulin treatment for patients with T2DM; and Analyse current efficacy...

Visit https://www.peervoice.com/VSB860 to view the entire programme with slides. After completing “Melanie J. Davies, CBE, FRCP, FMedSci / Linong Ji, MD - Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Established Therapies”, participants will be able to: Describe the importance of optimal cost-effective approaches to the pharmacologic management of type 2 diabetes mellitus (T2DM); Evaluate the role of established medications for T2DM for avoiding potential cardiorenal...

Visit https://www.peervoice.com/RSW860 to view the entire programme with slides. After completing “Sarah Jarvis, MBE, FRCGP - Achieving Shared Goals Across the Spectrum of CKD and HF”, participants will be able to: Identify patients at risk for and with chronic kidney disease (CKD) and heart failure (HF) based on early clinical indicators to expedite diagnosis and interventions; Recognise common barriers to evidence-based implementation of SGLT2 inhibition and strategies to overcome them; and...

Visit https://www.peervoice.com/FZR860 to view the entire programme with slides. After completing “Mansoor Husain, MD - Integrating GLP-1 RAs Into Our Cardiology Care Pathways: Who, When, and Why?”, participants will be able to: Identify the current place in therapy for GLP-1 receptor agonists (RAs) within guideline-recommended treatment algorithms for type 2 diabetes mellitus (T2DM); Evaluate current efficacy and safety data related to the effects of GLP-1 RAs on glycaemia, cardiometabolic...

Visit https://www.peervoice.com/GYQ860 to view the entire programme with slides. After completing “Kieran McCafferty, MB BChir, MRCP, MD (res) / Shelley Zieroth, MD, FRCPC, FHFSA (hon) - Handling Hyperkalaemia Without Compromising Care for Chronic Kidney Disease and Heart Failure”, participants will be able to: Evaluate the impact of hyperkalaemia and its implications for cardiovascular and renal protection and disease management; Apply current evidence and guidance for the use of potassium...

Visit https://www.peervoice.com/BPC860 to view the entire programme with slides. After completing “Sarah Jarvis, MBE, FRCGP - Identifying Intervention Points in CKD and HF From Multidisciplinary Viewpoints”, participants will be able to: Evaluate the impact of early identification and intervention on overall progression and outcomes of chronic kidney disease (CKD) and heart failure (HF); Recognise key points in the disease course of CKD and HF at which intervention is warranted to improve...

Visit https://www.peervoice.com/GHP860 to view the entire programme with slides. After completing “Optimizing Glycemic Control With GLP-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Risk: Translating the Evidence to Practice”, participants will be able to: Apply clinical practice guidelines to optimize early initiation of GLP-1 receptor agonists (RAs) in patients with type 2 diabetes (T2D) and cardiovascular (CV) risk; Outline practical patient management considerations...

Visit https://www.peervoice.com/NND860 to view the entire programme with slides. After completing “Elissa Weinberg, MD, BSc, CCFP, FCFP - Improving Glycemic Control in Adults With Type 2 Diabetes: A Need for Change”, participants will be able to: Outline the mechanism of action of GLP-1 receptor agonists (RA) and the dual-acting glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs; Discuss the latest evidence with GIP/GLP-1 RAs in the treatment of type 2 diabetes (T2D); Identify...

Visit https://www.peervoice.com/SMM860 to view the entire programme with slides. After completing “Verónica Vázquez Velázquez, PhD - Optimising Obesity Care in Adolescent Patients: Practical Blueprints to Overcome Barriers”, participants will be able to: Recognise the consequences of obesity on short- and long-term adolescent health; Apply recommended strategies for communicating treatment goals and therapeutic options with adolescent patients with obesity and their families or caregivers;...

Visit https://www.peervoice.com/TUZ860 to view the entire programme with slides. After completing “George L. Bakris, MD, MA - Step-by-Step: Setting a Course for Managing CKD and T2DM With Nonsteroidal MRAs”, participants will be able to: Describe the role of nonsteroidal mineralocorticoid receptor antagonists (MRAs) as part of an overall treatment strategy to improve renal and cardiovascular outcomes for patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM); Outline...

Visit https://www.peervoice.com/XAA860 to view the entire programme with slides. After completing “Luis Alberto Moreno, MD, PhD / Aaron Kelly, PhD - Assessing and Alleviating the Weight of Obesity in Adolescent Patients”, participants will be able to: Describe the burden and long-term effects of adolescent obesity; Discuss the benefits and limitations of current obesity care strategies in adolescent patients with obesity; and Evaluate the potential impact of emerging therapies on obesity in...

Visit https://www.peervoice.com/GVG860 to view the entire programme with slides. After completing “Kevin Fernando, FRCGP, FRCP Edin., FAcadMEd - Simplified Strategies to Optimise Obesity Management for Primary Point of Contact Clinicians”, participants will be able to: Recognise the role of novel pharmacologic options in the current management paradigm for obesity; Apply guidelines and evidence to improve weight management and outcomes in patients with obesity; and Use practical approaches to...

Visit https://www.peervoice.com/AFX860 to view the entire programme with slides. After completing “Angela Fitch, MD, FACP, Dipl. ABOM - Give the Heart a Break: Improving Cardiovascular Risk and Outcomes With Modern Weight Management Strategies”, participants will be able to: Define the impact of obesity on cardiovascular (CV) risk and the development of and mortality from CV disease; Discuss the role of anti-obesity medications, including GLP-1 receptor agonists (RAs), in the management of...

Visit https://www.peervoice.com/YUP860 to view the entire programme with slides. After completing “Jens Lundgren, MD - Applying Current European Guidance on Treating COVID-19 in Hospitalized Patients”, participants will be able to: Identify which patients hospitalised for a reason other than COVID-19 (but have mild/moderate COVID-19 symptoms) require antiviral therapy; Explain the rationale for not using a corticosteroid in patients hospitalised with COVID-19 who do not require supplemental...

Visit https://www.peervoice.com/DVE860 to view the entire programme with slides. After completing “Samuel Seidu, MD, FRCGP, FRCP (Edin) - The Power of the Primary Point of Contact: Taking Obesity From Obstacle to Opportunity”, participants will be able to: Recognise the significance and long-term consequences of obesity and weight bias; Manage patients with obesity using the principles of chronic disease state management; and Assess the impact of recommended pharmacologic interventions on...